Celgene and BeiGene enter multi-faceted $1bn+ immuno-oncology deal
Celgene Corp. licensed exclusive rights to BeiGene (Beijing) Co. Ltd.’s PD-1 inhibitor BGBA317 as part of a deal that also sees BeiGene acquiring Celgene’s Chinese commercial operations and rights in China to key Celgene therapies.
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Product or Technology Swap
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.